Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237703 · ClinicalTrials.gov registry record
Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 17
- Enrollment target
NCT02237703 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 17 participants.
The verdict
NCT02237703 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This study uses positron emission tomography (PET) imaging to measure kappa opioid receptors (KOR) in the brains of individuals with and without post-traumatic stress disorder (PTSD). The investigators propose to recruit 45 drug-naïve individuals, N=15 patients with PTSD, N=15 trauma-exposed, but asymptomatic healthy control subjects (TC) and N=15 non-trauma exposed healthy control subjects (HC) to participate in one magnetic resonance imaging (MRI) and one PET study. The investigators will also carefully document trauma history, and collect behavioral and neuroendocrine measures to provide a more integrative view on the neurobiology of PTSD and its phenotype. The investigators predict PTSD will show greater carbon - 11 (11C)\[11C\]LY2795050 volume of distribution (VT) (i.e. KOR binding) values than control populations in an a priori defined PTSD circuit.
Interventions
- OTHER Positron emission tomography (PET) imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2012-03 |
| Est. Completion | 2016-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237703
The ClinicalTrials.gov registry entry for NCT02237703 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Positron emission tomography (PET) imaging is the first listed.
NCT02237703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237703 about?
NCT02237703 is a clinical study titled "Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)". This study uses positron emission tomography (PET) imaging to measure kappa opioid receptors (KOR) in the brains of individuals with and without post-traumatic stress disorder (PTSD). The investigators propose to recruit 45 drug-naïve individuals, N=15 patients with PTSD, N=15 trauma-exposed, but as...
What is the current status of trial NCT02237703?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2012-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02237703?
The interventions under investigation include: Positron emission tomography (PET) imaging (OTHER).
Who is sponsoring clinical trial NCT02237703?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.